Thrombosis
From the Journals
Low-dose prasugrel preserves efficacy but lowers bleeding in elderly
In an ISAR-REACT 5 substudy of elderly ACS patients, low-dose prasugrel was favored over ticagrelor.
From the Journals
New oral anticoagulants drive ACC consensus on bleeding
A new consensus document from the American College of Cardiology updates management of acute bleeding in patients on oral anticoagulants.
From the Journals
PCI or not, mortality climbs with post-ACS bleeding complications
Prevention of bleeding after ACS, whether managed medically or with PCI, should get as much attention as prevention of later ischemic events.
Conference Coverage
Chewed prasugrel for primary PCI? Forget it!
Tirofiban tops cangrelor for platelet inhibition in ST-elevation MI.
Clinical Insights
Endothelial injury may play a major role in COVID-19–associated coagulopathy
From the Journals
LAA Closure noninferior to DOACs to prevent AF-related events
Left atrial appendage occlusion offers nondrug alternative to stroke prevention for atrial fibrillation patients.
Conference Coverage
TNF inhibitors cut odds of VTE in RA patients
Rather than increase risk for venous thromboembolism events, TNF inhibitors cut risk by nearly half, and other newer biologics lowered risk by...
News
Ticagrelor gets FDA nod for DAPT in high-risk patients with CAD
The new indication is based on THEMIS, which comprised patients with CAD and type 2 diabetes without previous MI or stroke and showed clinical...
Conference Coverage
Onyx stent meets DAPT performance goal in bleeding-risk patients
A zotarolimus-eluting coronary stent met its FDA-set performance goal in high-bleeding-risk patients on dual antiplatelet therapy for 1 month.
Guidelines
Societies offer advice on treating osteoporosis patients during pandemic
General and specific recommendations from leading bone health organizations shine a light on how to manage osteoporosis patients during the COVID-...
From the Journals
Evidence builds linking anticoagulation to COVID-19 survival
“Any family of mine who will have this disease absolutely will be on antithrombotic therapy and, actually, so are all of the patients at Mount...